Clinical Trial Update: Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 1/2 results for MOR202 in anti-PLA2R positive membranous nephropathy, with the study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• MOR202

Snippet

Sponsor: HI-Bio, A Biogen Company | Conditions: Glomerulonephritis, Membranous, antiPLA2R Positive | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-24